Translational, Bioethical, and Global Equity Challenges in the Deployment of Anti-HIV Biotherapies: From the Research Laboratory to the Most Affected Populations
Loading...
Files
Date
Authors
Barack Ndenga
Journal Title
Journal ISSN
Volume Title
Publisher
Publisher
Abstract
Over the past two decades, HIV research has entered an era of unprecedented technological sophistication, marked by advances in gene therapy, immuno-engineered cells, nanomedicine, and precision vaccines. Yet, I argue that scientific feasibility alone does not guarantee clinical impact. The translation of cutting-edge biotherapies into real-world benefit is constrained by ethical, logistical, economic, and geopolitical barriers—particularly in regions most affected by HIV. In this article, I critically examine the translational bottlenecks, bioethical dilemmas, and global equity challenges associated with next-generation anti-HIV biotherapies. I conclude that the ultimate success of HIV cure strategies will depend not only on biological efficacy, but on ethical legitimacy, societal trust, and deliberately engineered accessibility.
Keywords : HIV cure,Global health
equity,Bioethics,Translational research,Health justice,Biotherapy deployment,Manufacturing scalability,Regulatory frameworks,
Access to medicines,Health systems strengthening,Gene therapy,Cell therapy,Low- and middle-income countries (LMICs),
Community engagement,Health policy
Description
This article confronts the most critical, non-biological frontier in the quest for an HIV cure: the ethical and logistical deployment of advanced biotherapies. As research advances toward sophisticated gene, cell, and immuno-engineering strategies, I argue that scientific feasibility alone is insufficient. This work critically examines the translational bottlenecks—from manufacturing scalability to regulatory fragmentation—and the profound bioethical dilemmas arising from deploying irreversible interventions in a non-fatal, managed disease. Most centrally, it analyzes the imminent risk of a two-tier global cure landscape and advocates for the principle of "equity-by-design"—the deliberate integration of accessibility, affordability, and justice into the core architecture of next-generation therapies. The success of an HIV cure will be measured not only in viral load, but in global health equity.